Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 3/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 13/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA12 | O43570 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16646098 | 0.83 | ALOX12 (1.00) | ALOX12ALOX15 | |
| SCHEMBL32677284 | 0.83 | ALOX12 (1.00) | ALOX12ALOX15 | |
| SCHEMBL29056403 | 0.82 | LMNA (0.55) | LMNASMN1; SMN2NPSR1CA2ACHE | |
| SCHEMBL16646069 | 0.81 | ALOX12 (1.00) | LMNAALOX12ALOX15 | |
| SCHEMBL25233068 | 0.81 | ALOX12 (0.72) | LMNASMN1; SMN2NPSR1ALOX12ALOX15 | |
| SCHEMBL16634501 | 0.80 | ALOX12 (1.00) | ALOX12ALOX15 | |
| SCHEMBL16646066 | 0.80 | ALOX12 (1.00) | ALOX12ALOX15 | |
| SCHEMBL18370585 | 0.80 | CA1 (1.00) | LMNASMN1; SMN2NPSR1CA2ACHE | |
| SCHEMBL21344768 | 0.80 | ALOX12 (0.61) | LMNASMN1; SMN2NPSR1ALOX12ALOX15 | |
| SCHEMBL21504072 | 0.80 | MAPT (0.61) | LMNASMN1; SMN2NPSR1ALOX12ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452250-A4 | AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENE SULFONAMIDE DERIVATIVES | VERALOX THERAPEUTICS INC (US) | 2025-12-31 | — | — | EP | disclosed |
| EP-4612135-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Veralox Therapeutics Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612135-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Veralox Therapeutics Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612135-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Veralox Therapeutics Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120435464-A | Oral pharmaceutical formulations containing 4- ((2-hydroxy-3-methoxybenzyl) amino) benzenesulfonamide derivatives | 维拉洛斯治疗公司 | 2025-08-05 | — | — | CN | disclosed |
| CN-120435464-A | Oral pharmaceutical formulations containing 4- ((2-hydroxy-3-methoxybenzyl) amino) benzenesulfonamide derivatives | 维拉洛斯治疗公司 | 2025-08-05 | — | — | CN | disclosed |
| US-20250057857-A1 | AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Cadrenal Therapeutics, Inc. | 2025-02-20 | — | — | US | disclosed |
| US-20250057857-A1 | AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Cadrenal Therapeutics, Inc. | 2025-02-20 | — | — | US | disclosed |
| US-20250057857-A1 | AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Cadrenal Therapeutics, Inc. | 2025-02-20 | — | — | US | disclosed |
| EP-4452250-A1 | AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENE SULFONAMIDE DERIVATIVES | Veralox Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-3054936-A4 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | Eastern Virginia Medical School (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170001955-A1 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase | THOMAS JEFFERSON UNIVERSITY | 2017-01-05 | — | — | US | disclosed |
| US-20170001955-A1 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase | THOMAS JEFFERSON UNIVERSITY | 2017-01-05 | — | — | US | disclosed |
| US-20170001955-A1 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase | THOMAS JEFFERSON UNIVERSITY | 2017-01-05 | — | — | US | disclosed |
| EP-3054936-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | Eastern Virginia Medical School (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-3054936-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | Eastern Virginia Medical School (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-3054936-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | Eastern Virginia Medical School (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054662-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054662-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054662-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001955-A1 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase | ALOX12, ALOX15, ALOX15B | LMNA 1518/4885SMN1; SMN2 3002/4885NPSR1 1312/4885 |
| US-20250057857-A1 | AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | LOX, LOXL2, LOXL4 | LMNA 1030/4885SMN1; SMN2 1048/4885NPSR1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.